Compare IDEXX Laboratories, Inc. (IDXX) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs RLX Technology Inc — how do they compare? IDEXX Laboratories, Inc. trades at $546.1 (market cap $43.58B), while RLX Technology Inc trades at $2.05 (market cap $2.47B). The key difference: IDEXX Laboratories, Inc. is far larger — about 17.6× RLX Technology Inc's market cap, and RLX Technology Inc pays a 4.95% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | RLX | |
|---|---|---|
Market Cap | $43.58B | $2.47B |
Sector | Health | Technology |
52-Week High | $766.68 | $2.73 |
52-Week Low | $526.44 | $1.79 |
Enterprise Value | $44.48B | $1.10B |
Dividend Yield | — | 4.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
RLX trades at $2.06, up 0.49% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 revenue growth driven by international expansion, with 2025 net income of $921.87M and a net margin of 22.47%. Recent news highlights the company's cash-rich, debt-free position and its positioning in the growing global vaping market.
The outlook is mixed; strong fundamentals and market growth potential are offset by consecutive earnings misses and a single analyst's hold rating. Key risks include regulatory scrutiny in the vaping industry and execution challenges in international expansion. The stock presents a speculative opportunity for investors comfortable with sector-specific regulatory risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
